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Summary
Background: Upon St. Gallen consensus conference (1) and updated version of NCCN guidelines (2) from 2017, in 
May 2017 in Clinical Hospital Center Rijeka sentinel lymph node biopsy (SLNB) was introduced in clinical practice for axil-
lary staging of breast cancer patients that achieved complete clinical axillary remission after neoadjuvant systemic onco-
logic treatment.
This trial aims to evaluate the clinical impact of SLNB performance after neoadjuvant systemic treatment (NAST) in 
initially node-positive breast cancer patients and to determine the prognostic value of the axillary complete pathological 
response.
Patients and Methods: Breast cancer patients in clinical stage T1-T3 N0-N2 M0, surgically treated in our institution 
from September 2018 till May 2022 would be included in this trial and divided into three groups according to protocol. 
SLNB would be performed in all patients presenting with cN0 stage at the time of surgery, including those patients who 
shift from cN1-N2 to cN0 during NAST. All patients involved in this trial would be monitored for five postoperative years 
in order to determine following parameters: rates of local and regional recurrence, rate of disease progression to M1 stage, 
regional recurrence-free survival, disease progression-free survival, cancer-related mortality rate, and overall survival.
Results: Results gained from this trial would be compared among groups and with our previous data of patients in 
equivalent stage treated in period from 2011 till 2014 when all patients were primary surgically treated, therefore axillary 
lymph node dissection (ALND) was performed for all node-positive patients.
Conclusion: Hopefully, the results of this trial would provide enough evidence that SLNB performance after NAST 
does not have a negative impact on clinical outcome in breast cancer patients who had reached complete clinical axillary 
remission. In addition, we would try to determine the prognostic value of the axillary complete pathologic response.
ClinicalTrials.gov: This protocol has been registered at clinicaltrials.gov with ID: NCT03719833
Abbreviations: SLNB=sentinel lymph node biopsy, ALND=axillary lymph node dissection, NAST=neoadjuvant sys-
temic treatment, US=ultrasound, MRI= magnetic resonance imaging, RRR=regional recurrence rate, RRFS=regional recur-
rence-free survival, DFS=disease free survival, CSMR=cancer specific mortality rate, OS=overall survival
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UTJECAJ BIOPSIJE SENTINEL LIMFNOG ČVORA NAKON NEOADJUVANTNOG SISTEMSKOG LIJEČENJA NA 
KLINIČKI ISHOD BOLESNICA OBOLJELIH OD LUMINAL B, HER-2 POZITIVNOG I TROSTRUKO NEGATIVNOG 
KARCINOMA DOJKE SA INICIJALNO METASTATSKI ZAHVAĆENIM AKSILARNIM LIMFNIM ČVOROVIMA
Protokol prospektivnog, nerandomiziranog, opservacijskog kliničkog istraživanja
Sažetak
Uvod: Temeljem konsenzusa konferencije u St. Gallen-u i revidiranih NCCN-ovih smjernica za liječenje raka dojke iz 
2017., u svibnju iste godine u KBC-u Rijeka biopsija sentinel limfnog čvora (SLNB) uvedena je u kliničku praksu kao metoda 
izbora procjene aksilarnog stadija za bolesnice oboljele od karcinoma dojke sa inicijalno zahvaćenom aksilom, a koje su 
 neoadjuvantnim sistemskim liječenjem (NAST) postigle kompletnu kliničku aksilarnu remisiju.
Kako bi evaluirali utjecaj izvođenja SLNB nakon NAST na ishod liječenja kod spomenute skupine pacijentica i poku-
šali objektivizirati prognostički značaj kompletnog patološkog aksilarnog odgovora (pCR) osmislili smo protokol prospek-
tivnog opservacijskog kliničkog istraživanja.
Pacijenti i metode: U istraživanje će biti uključene bolesnice oboljele od karcinoma dojke u stadiju T1-T3 N0-N2 M0, 
kirurški liječene u KBC Rijeka u periodu od rujna 2018. do svibnja 2022. Iste će biti podijeljene u tri grupe u skladu sa defi-
niranim protokolom. SLNB će se učiniti kod svih bolesnica koje se preoperativno prezentiraju u stadiju cN0, uključujući i 
bolesnice koje su se neoadjuvantnim liječenjem konvertirale iz stadija cN1-N2 u stadij cN0. U petogodišnjem postoperativ-
nom periodu pratit će se pojavnost lokalnog i regionalnog recidiva, progresije bolesti u M1 stadij, smrtnost od karcinoma i 
sveukupno preživljenje.
Rezultati: Rezultati će se usporedit između skupina definiranih protokolom ovog istraživanja te sa rezultatima skupi-
na bolesnica ekvivalentnog stadija bolesti liječenih u periodu od 2011. do 2014. kada su bolesnice bile primarno kirurški 
 liječene, odnosno kada je svim bolesnicama sa inicijalno pozitivnim aksilarnim limfnim čvorovima standardno učinjena 
aksilarna disekcija (ALND).
Zaključak: Dobivenim rezultatima želimo potvrditi osnovnu hipotezu ovog istraživanja; da procedura SLNB nakon 
NAST nema negativan utjecaj na ishod liječenja kod bolesnica sa inicijalno pozitivnom aksilom koje su preoperativnom 
 sistemskom terapijom postigle remisiju bolesti u aksili. Uz navedeno pokušat ćemo odrediti prognostički značaj down-
staging-a aksile neoadjuvantnim liječenjem. ClinicalTrial.gov: Protokol istraživanja je registriran i javno dostupan na strani-
cama www.clinicaltrials.gov (ID:NCT03719833)
KLJUČNE RIJEČI:  biopsija sentinel limfnog čvora, neoadjuvantna terapija, pozitivni limfni čvor, kompletni odgovor,  
regionalni recidiv
BACKGROUND
1. Introduction
Until recently, axillary lymph node dissec-
tion was the standard approach in axillary surgery 
after neoadjuvant treatment of operable breast 
cancer, due to controversy about the reliability of 
sentinel lymph node biopsy after primary system-
ic treatment. Although the initial researches (3,4,5) 
had a wide range of identification rate (IR) and 
high false-negative rates (FNR), the following tri-
als (6-15) offered optimization methods resulting 
with 95% IR and less than 10% FNR., which is 
equal to IR and FNR of SLNB performance for 
early breast cancer. Therefore, in 2017 a consensus 
was reached at a conference in St. Gallen (1), and 
in same time updated version of NCCN guide-
lines for breast cancer treatment (2) declares the 
recommendation for SLNB performance after 
NAST in breast cancer patients presenting with 
uninvolved axilla at the time of surgery. In May 
2017, the practice was accepted in Clinical Hospi-
tal Center Rijeka. Current clinical experience and 
preliminary results of our retrospective analysis 
have not shown any negative impact on the clini-
cal outcome of these patients. To confirm these 
observations, we initiated a prospective clinical 
trial in September 2018.
2. Hypotheses
There are two main hypotheses of this trial. 
First, SLNB does not have a negative impact on 
clinical outcome in initially node-positive breast 
cancer patients who achieved clinical axillary re-
mission following NAST and second, lymph node 
status after NAST is significantly more relevant 
prognostic factor than nodal status at the time of 
diagnosis. In addition, we wish to evaluate if iden-
tification and biopsy of pre-neoadjuvant positive 
node(s) significantly increase the reliability of 
SLNB, to determine the correlations of axillary 
pathologic complete response and the characteris-
31
Lib Oncol. 2019;47(1):29–34
tics of primary tumor and to evaluate the accuracy 
of axillary ultrasound (US) and standard breast 
magnetic resonance imaging (MRI) in axillary re-
evaluation after NAST.
PATIENTS AND METHODS
1. Study design
The present clinical study is a prospective, 
observational, non-randomised clinical trial of the 
overall duration of 8-9 years. In the recruiting 
phase, that would last for 3-4 years. The investiga-
tors would create three predetermined cohorts of 
breast cancer patients, all eventually submitted to 
surgery. We will include 50 patients in each arm, 
based on the available study and our patient vol-
ume. We will try to include other centers in Croa-
tia soon. First results and conclusions (regarding 
our secondary endpoints) could be reached at the 
end of this phase. In the second phase, follow up 
period of five postoperative years, all patients in-
volved in this trial would be periodically moni-
tored for, earlier mentioned primary endpoints of 
this trial.
2. Inclusion and exclusion criteria
All female breast cancer patients from 18 to 
80 years old, presenting in clinical stage T1-T3 N0-
N2 M0, surgically treated in Clinical Hospital 
Center Rijeka in the period from September 2018 
till May 2022, would be involved in this trial. 
However, patients should have biopsy-proven 
ductal breast cancer, Luminal B, HER-2 positive or 
triple-negative subtype and those patients with 
nodal disease should have cytological proof of 
metastatic disease and marked positive node(s) 
with titanium clip at the onset of NAST. Further-
more, patients in T2-T3 and/or N1-N2 stage must 
be eligible for systemic oncological treatment, ac-
cepting to undergo it and complete it. All patients 
involved in the trial must understand, accept and 
signed the approved consent form.
Patients with bilateral disease, unilateral re-
currence, previous axillary surgery or axillary ra-
diotherapy, treated or in treatment for another 
malignant disease and patients without complete 
documentation required for this study would be 
excluded.
3. Groups
Based on US and/or MRI assessment of pri-
mary tumor dimensions, pathological report of 
core needle biopsy, US evaluation of axillary lymph 
node status and cytological proof of involved 
node(s), patients would be allocated in following 
groups; group 1 (T1 N0 M0), group 2 (T2-T3 N0-
N2 M0) and group 3 (T1-T3 N1-N2 M0).
4. Protocol
All patients would be subjected to ultrasound 
(US) assessment of primary tumor dimensions, 
US-guided core needle biopsy of the primary tu-
mor and the axillary US. For all suspicious nodes, 
US-guided fine-needle aspiration cytology would 
be made. Patients in T1N0 stage would be as-
signed to group 1 and subdue to surgery (lumpec-
tomy and SLNB), following by adjuvant systemic 
oncological treatment. For stage T2-T3 patients 
breast MRI would be done and titanium clip 
placement at the primary tumor site. For stage N1 
patients, titanium clip would be placed in cytolo-
gy proven metastatic node(s). According to N sta-
tus, patients would be allocated to group 2 or 3 
and subdue to neoadjuvant systemic treatment 
lasting 24 weeks, following by surgery and adju-
vant oncological treatment. At the end of NAST, 
all patients would be submitted to breast MRI for 
evaluation of the clinical response of the primary 
tumor to NAST and those with initially involved 
nodes would be subdued to axillary reevaluation 
by US.
All MRI exams would be performed with a 
1,5T unit (MAGNETOM Avanto; Siemens Medical 
Solutions, Erlangen, Germany) with a dedicated 
bilateral eight-channel breast coil. The axillary ul-
trasound would be performed with a high-fre-
quency linear array transducer up to 15 MHz on 
LOGIQ S8® (General Electric Medical Systems, 
Milwaukee, USA). Lymph node(s) would be cate-
gorized as suspicious if they exhibited one or 
more of the following characteristics: loss of cen-
tral fatty hilum/thinning of hilum, eccentric thick-
ening of the cortex, heterogenous echotexture, ill-
defined capsular margins and irregular or round 
shape.
SLNB would be done for all patients present-
ing preoperative with cN0 stage, and for group 3 
patients, titanium marked node(s) would be sur-
gically removed along with SLNB procedure.
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Background of sentinel lymph node(s) detec-
tion would be lymphoscintigraphy with 99mTc-
labeled nano colloid (Nanocoll). On an operating 
day, radiocolloid would be injected intradermally 
in the breast, and preoperative plane scintigraphy 
would be done after 30 minutes. Intraoperatively 
hand-held gamma detecting probe (Neoprobe® 
Gamma Detecting System) would be used in or-
der to detect sentinel node(s).
All biopsied nodes would be examined intra-
operatively by imprint cytology and on frozen 
sections by HE staining. The final pathological re-
port would be made on paraffin-embedded sec-
tions by HE staining and panCK. In the pathologic 
report, positive node after NAST would be con-
sidered any node that contains residual tumor re-
gardless of the size of the tumor. For the presence 
of any residual nodal disease after NAST, ALND 
would be performed.
The pathological stage would be defined ac-
cording to the current TNM classification by the 
AJCC Cancer Staging Manual.
In postoperative five years follow up period, 
all patients would be monitored for the appear-
ance of local and regional recurrence, progression 
of the disease to M1 stage and cancer-related 
death.
RESULTS
1. Outcome measures
Primary endpoints are: rates of local and re-
gional recurrence, a progression of the disease to 
M1 stage rate, regional recurrence-free survival 
(RRFS), disease progression-free survival (DPFS), 
cancer-related mortality rate and overall survi- 
val (OS).
Secondary endpoints are: correspondence 
rate between metastatic marked node and non-
sentinel nodes, correlations of axillary complete 
pathologic remission and characteristics of prima-
ry tumor (subtype, grade, size, proliferation in-
dex, presence of lymphovascular invasion and 
pathologic complete response of primary tumor), 
sensitivity, specificity, positive predictive value 
and negative predictive value of axillary US and 
standard breast MRI in axillary assessment after 
NAST.
All relevant data would be collected on pa-
tients checklists and summarized in a table at the 
end of this trial for statistical analysis.
2. Statistical analysis
The Statistica 13.0 commercial software (Stat-
soft Inc., Tulsa, OK, USA) and the statistical sig-
nificance level at p<0.05 would be used for statisti-
cal calculations. To test relationships between cat-
egorical variables, we would use either the 
Chi-square test, Fisher exact test, or the McNemar 
test. Spearman’s correlation, as well as logistic re-
gression, would be used for testing the associa-
tions between axillary pathological complete re-
mission and biological characteristics of the pri-
mary tumor.
DISCUSSION
The impact of sentinel lymph node biopsy 
procedure after neoadjuvant systemic therapy in 
initially node involved breast cancer patients who 
achieved complete clinical axillary remission 
needs assessment. in this trial we would compare 
regional recurrence rate (RRR) and regional recur-
rence-free survival (RRFS) of group 3 to RRR and 
RRFS of group 1 and group 2 and to RRR and 
RRFS from our former data (group of patients in 
equivalent initial stage treated without NAST, 
therefore ALND was performed for all node-posi-
tive patients). Based on our current clinical experi-
ence and the preliminary results of our retrospec-
tive analysis we expect that the RRR and RRFS of 
group 3 patients would not be significantly worse 
than in the group of patients in whom ALND was 
performed, moreover, we expect them to be even 
better (i.e. lower RRR and higher RRFS). Also, we 
want to determine if these results of the third 
group differ significantly from the results of the 
first and second group of patients.
In order to try to objectively estimate prog-
nostic value of axillary pathologic complete re-
sponse, we will compare disease-free survival 
(DFS), cancer-specific mortality rate (CSMR) and 
overall survival (OS) of sentinel node-negative pa-
tients from group 3 to DFS, CSMR and OS of node-
positive patients from group 3 and to group of 
patients of equivalent initial nodal status treated 
in period from 2011 till 2014 (i.e. without NAST 
and with ALND).
To determine the significance of node mark-
ing procedure for the accuracy of SLNB after 
NAST in node-positive patients, we would try to 
determine the correspondence rate between a 
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marked node(s) and metastatic non-sentinel 
node(s). According to our clinical experience, we 
believe that with the possibility of detecting and 
removing at least three sentinel nodes, this meth-
od might be safely omitted.
Based on sensitivity, specificity, negative pre-
dictive value and positive predictive value, and 
relative to breast cancer subtypes, we would try to 
evaluate the accuracy of the axillary US and stan-
dard breast MRI in axillary lymph node reevalua-
tion at the end of neoadjuvant treatment. Thereby 
we would estimate the possibility of undertreat-
ment and overtreatment with surgeons’ decision 
on the extent of axillary surgical procedure guid-
ed by radiological indications.
We would determine the axillary pathologic 
complete remission rate in correlation with tumor 
subtypes to assess whether involved axillary 
lymph node(s) at presentation is an absolute indi-
cation for NAST, regardless pathological charac-
teristic of the primary tumor and the size of the 
primary tumor.
CONCLUSIONS
Recent studies (6-14) have shown that SLNB 
is an acceptable alternative of ALND for axillary 
staging after NAST in initially node-positive 
breast cancer patients who shift to node-negative, 
with IR of 95% and less than 10% of FNR. Our 
clinical experience and preliminary results of our 
retrospective analysis, as well as the results from 
an Italian retrospective analysis (16), suggest that 
SLNB performance following NAST does not have 
a negative impact on clinical outcome in initially 
node-positive breast cancer patients. Moreover, 
we strongly believe that this subgroup of patients 
from our third cohort are exactly those patients 
with the best prognosis.
We hope that this clinical trial would provide 
enough evidence for the above statements, there-
by contribute to the acceptance of SLNB perfor-
mance after NAST and enable the avoidance of all 
unnecessary ALND.
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